Skip to content

Anxiety and Depression Disorder in Patient Treated With rTPA for Mangment of Acute Ischemic Stroke

Anxiety and Depression Disorder in Patient Treated With rTPA for Mangment of Acute Ischemic Stroke

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04484558
Enrollment
40
Registered
2020-07-23
Start date
2020-01-01
Completion date
2021-12-01
Last updated
2020-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Stroke, Anxiety Disorders, Depression

Brief summary

In fact theWorld Health Organization estimates that 2-3% in general populations of countries across the world tend to be affected by severe mental disorders (1) Thrombolytic therapy seems to be of great importance in achieving better quality of life in ischemic stroke patients who respond to this therapy(rTPA).

Detailed description

There is a substantial body of evidenc suggesting a strong relation between neurotrophic factors and depression and anxiety pathogenesis (2,8) Brain-derived neurotrophic factor (BDNF), a member of the neurotrophic family known to regulate neuronal plasticity and survival , may play an important role in the pathophysiology of depression and anxiety (3,9). Different studies indicated patients who were exposed to traumatic events have anxiety comorbidity and lower levels of serum BDNF compared to those without a history of traumatic events (4) . BDNF has an antidepressant and anxiolytic effect which suggest that BDNF is implicated in the regulation of anxiety-related behaviors. which leads to a valine-to-methionine change in the proBDNF protein, was associated with lower activity-dependent secretion of BDNF (5)and has been implicated with increased susceptibility to neuropsychiatric disorders including depression, anxiety-related dysfunction, and bipolar disorder , all these studies suggest that BDNF is likely to be an important etiological factor in memory, depression and anxiety disorders (6,10). BDNF arises from a precursor, proBDNF, which is cleaved to produce the mature protein through the tissue plasminogen activator (tPA) pathway, and represents one mechanism that can regulate the action of BDNFarises from a precursor, proBDNF, which is cleaved to produce the mature protein through the tissue plasminogen activator (tPA) pathway, and represents one mechanism that can regulate the action of BDNF (7). The purpose of this study is to examine the quality of life after stroke of patients treated with thrombolysis .

Interventions

Infusion

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years

Inclusion criteria

1. age more than 40. 2. None of the pt had history of other psychiatric illness. 3. male and female.

Exclusion criteria

* 1-smoker. 2-substance abuser or dependence. 3-History of other psychiatric illness. 4-History of other neurological illness.

Design outcomes

Primary

MeasureTime frameDescription
Detection and measureing anxiety and depressive symptoms in ischemic stroke patients treated with rtpA .15 minutesHamilton depression and anxiety rating scale

Secondary

MeasureTime frameDescription
Measuring quality of life in patients with ischemic stroke treated wih rtpA .10 minutesQuality of life questionnaire

Countries

Egypt

Contacts

Primary ContactEbtsam Mohamed Tawfik
ebtsamtawfik393@gmail.com+0201001297992

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026